3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Multiple Myeloma
45
Recurrence
14
Lymphoma
6
Neoplasms
5
Neoplasms, Plasma Cell
4
Lymphoma, Large B-Cell, Diffuse
4
Waldenstrom Macroglobulinemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Immunoglobulin Light-chain Amyloidosis
2
Hodgkin Disease
2
Glioblastoma
2
Amyloidosis
2
Wilms Tumor
1
Vomiting
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Ototoxicity
1
Osteosarcoma
1
Obesity
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Interventions
Nivolumab
17
Ipilimumab
14
pembrolizumab
11
Cyclophosphamide
8
trametinib
7
dabrafenib
6
Interleukin-2
6
aldesleukin
5
Vemurafenib
5
Radiotherapy
5
sargramostim
4
130-nm albumin-bound paclitaxel
4
fludarabine
3
encorafenib
3
binimetinib
3
Specimen Handling
3
Radiosurgery
3
Melphalan
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
fludarabine phosphate
2
Magnetic Resonance Spectroscopy
2
Introns
2
Infliximab
2
Celecoxib
2
CTLA-4 Antigen
2
Biopsy
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
yeast-CEA vaccine
1
vitespin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Melanoma
×
Dexamethasone
×
Clear all
NCT02862145
2016-09-27
MRX34-102
Mirna Therapeutics, Inc.
Phase 1/2
Withdrawn